$BMRN $XBI $BBH $IBB $XLV alot of BS being thrown around on BMRN’s quarter. They beat both revenue and EPS. Kuvan sales in line with forecast FDA Vor review extended to include new data. This is good news. With the new data, Vor looks approvable. Without not so much. And it was only a 3 month extension. Rox EMA on track. FDA requires 2 years of data. Witt RMAT one year could possibly be after approval, but I’mI not banking on it.Vor Chimp dec in June. In any case nei Vor or Rox is priced into the stock IMO!
1
1
1 Like